Compare SSMR & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSMR | KLRA |
|---|---|---|
| Founded | 2010 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2026 | 2026 |
| Metric | SSMR | KLRA |
|---|---|---|
| Price | $11.02 | $11.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $19.08 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 1.1M | 747.0K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $9.76 |
| 52 Week High | $19.61 | $23.82 |
| Indicator | SSMR | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 39.32 |
| Support Level | $11.00 | $9.76 |
| Resistance Level | $15.17 | $11.81 |
| Average True Range (ATR) | 1.12 | 0.98 |
| MACD | -0.09 | -0.22 |
| Stochastic Oscillator | 11.96 | 4.61 |
Sunshine Silver Mining & Refining Co is a mining exploration and development company. It owns and develops the Sunshine Mine, the Sunshine Silver/Copper Refinery, and related facilities, including the Sunshine Tailings Storage Facility and historical antimony refinery grounds. The Sunshine Mine is a permitted past-producing silver mine in the United States that has historically produced silver, antimony, copper, and lead.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.